Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 190

Sort by

Sort Order Select

Journal Articles

MARCKS affects cell motility and response to BTK inhibitors in CLL

Blood (2021) 138 (7): 544–556.

https://doi.org/10.1182/blood.2020009165

Published: 2021

Includes: Supplemental data

Journal Articles

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Ishwarya Murali, Siddha Kasar, Aishath Naeem, Svitlana Tyekucheva, Jasneet K. Khalsa, Emily M. Thrash, Gilad Itchaki, Dimitri Livitz, Ignaty Leshchiner, Shuai Dong, Stacey M. Fernandes, Gad Getz, Amy Johnson, Jennifer R. Brown

Blood (2021) 138 (1): 44–56.

https://doi.org/10.1182/blood.2020006765

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Blood (2021) 137 (25): 3473–3483.

https://doi.org/10.1182/blood.2020009688

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Blood (2020) 136 (1): 93–105.

https://doi.org/10.1182/blood.2019003715

Published: 2020

Includes: Supplemental data

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Gavin Cull, MB, BS, FRACP, FRCPA, David Simpson, MBChB, FRACP, FRCPA, Stephen Opat, Jan A. Burger, MD PhD, Judith Trotman, MBChB, FRACP, FRCPA, Paula Marlton, MBBS (Hons), FRACP, FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Javier Munoz, MD MS, FACP, John F. Seymour, MBBS, PhD FRACP, Andrew W. Roberts, MBBS, PhD, Ken Wu, PhD, Siminder Atwal, PhD, William Novotny, MD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 500.

https://doi.org/10.1182/blood-2019-125483

Published: 2019

Journal Articles

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Blood (2019) 134 (Supplement_1): 5476.

https://doi.org/10.1182/blood-2019-126402

Published: 2019

Journal Articles

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Jing Xie, Alan Yong, Catherine Waweru, PhD, Thuy Anh Sorof, Ravi K Goyal, MS, Keith L Davis, MA, George Follows, Peter Hillmen, MD PhD

Blood (2019) 134 (Supplement_1): 5885.

https://doi.org/10.1182/blood-2019-123025

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Changying Jiang, PhD, Rongjia Zhang, Shaojun Zhang, PhD, William Lee, Shengjian Huang, PhD, Yang Liu, MD, Angela Leeming, Joseph Mitchell McIntosh, Preetesh Jain, MBBS,MDDM,PhD, Krystle Nomie, PhD, Linghua Wang, PhD, Michael L. Wang, MD

Blood (2019) 134 (Supplement_1): 4062.

https://doi.org/10.1182/blood-2019-128299

Published: 2019

Journal Articles

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

David J. Kuter, Ralph V. Boccia, MD, Eun-Ju Lee, MD, Merlin Efraim, MD, Nikolay Tzvetkov, MD, Jiri Mayer, MD, Marek Trněný, MD, Milan Kostal, MD, Roman Hajek, MD, Vickie McDonald, MD, Olga Bandman, MD, Regan Burns, Ann Neale, Dolca Thomas, MD, Nichola Cooper, MD MRCP

Blood (2019) 134 (Supplement_1): 87.

https://doi.org/10.1182/blood-2019-122336

Published: 2019

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Deborah M. Stephens, DO, Ying Huang, MS, MA, Akwasi Agyeman, Amy S. Ruppert, MAS, PhD, Boyu Hu, MD, Natalie Turner, APRN, Renee Vadeboncoeur, MSN, APRN, Kerry A Rogers, MD, Seema A. Bhat, MD, Basem M. William, MRCP,MD, Samantha Jaglowski, MDMPH, Hank Lockman, Martha Glenn, MD, Rosa Lapalombella, PhD, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 4310.

https://doi.org/10.1182/blood-2019-124544

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Peter Hillmen, MD PhD, Jennifer R. Brown, MD PhD, John C. Byrd, MD, Barbara F. Eichhorst, MD, Nicole Lamanna, MD, Susan M. O'Brien, MD, Lugui Qiu, MD PhD, Tommi Salmi, MD, James Hilger, PhD, Jane Huang, MD, Constantine S. Tam, MBBS, MD

Blood (2019) 134 (Supplement_1): 4307.

https://doi.org/10.1182/blood-2019-124213

Published: 2019

Journal Articles

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

Elena Bibikova, Brian Law, Tracy Clevenger, PhD, Jean Cheung, MS, Gary De Jesus, Michael Gulrajani, Kyoko Yamaguchi, Phuong Do, Kathleen Burke, PhD, Graham Brock, PhD, Veerendra Munugalavadla, PhD, Melanie M. Frigault, PhD, John C. Byrd, MD, Richard R. Furman, MD, Jennifer R. Brown, MD PhD, Todd Covey

Blood (2019) 134 (Supplement_1): 2571.

https://doi.org/10.1182/blood-2019-128872

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Blood (2019) 134 (Supplement_1): 3039.

https://doi.org/10.1182/blood-2019-128706

Published: 2019

Journal Articles

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Maissa Mhibik, PhD, Erika M Gaglione, Amy Blackburn, Keyvan Keyvanfar, Clare Sun, MD, Inhye E Ahn, MD, Maria Joao Baptista, Junpeng Qi, PhD, Christoph Rader, PhD, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 2861.

https://doi.org/10.1182/blood-2019-126186

Published: 2019

Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Blood (2019) 134 (Supplement_1): 499.

https://doi.org/10.1182/blood-2019-125394

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

MARCKS affects cell motility and response to BTK inhibitors in CLL

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia

Phase 2 study of ibrutinib in classic and variant hairy cell leukemia

Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Treatment with the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrates High Overall Response Rate and Durable Responses in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Updated Results from a Phase 1/2 Trial

Efficacy and Safety of Ibrutinib Use in Patients with Chronic Lymphocytic Leukemia in Real World Experiences: Results of a Prospective Multicenter Study

Real-World Treatment Patterns and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib in the UK: A Preliminary Analysis

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma

Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

High Surface Expression of CD49d (VLA-4) and CD79b Correlates with Acalabrutinib Resistance in Patients with Chronic Lymphocytic Leukemia (CLL)

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib

Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only